{
  "id": [
    "32317153"
  ],
  "source": [
    "MED"
  ],
  "pmid": [
    "32317153"
  ],
  "pmcid": [
    "PMC7136878"
  ],
  "doi": [
    "10.1016/j.sapharm.2020.04.001"
  ],
  "title": [
    "Drugs supply and pharmaceutical care management practices at a designated hospital during the COVID-19 epidemic."
  ],
  "authorString": [
    "Ying W, Qian Y, Kun Z."
  ],
  "authorList": [
    {
      "author": [
        {
          "fullName": [
            "Ying W"
          ],
          "firstName": [
            "Wang"
          ],
          "lastName": [
            "Ying"
          ],
          "initials": [
            "W"
          ],
          "authorAffiliationsList": [
            {
              "authorAffiliation": [
                "Department of Pharmacy, The Third Hospital of Jilin University, Jilin University, Changchun, 130033, Jilin, China."
              ]
            }
          ]
        },
        {
          "fullName": [
            "Qian Y"
          ],
          "firstName": [
            "Yu"
          ],
          "lastName": [
            "Qian"
          ],
          "initials": [
            "Y"
          ],
          "authorAffiliationsList": [
            {
              "authorAffiliation": [
                "Department of Pharmacy, The Third Hospital of Jilin University, Jilin University, Changchun, 130033, Jilin, China."
              ]
            }
          ]
        },
        {
          "fullName": [
            "Kun Z"
          ],
          "firstName": [
            "Zhu"
          ],
          "lastName": [
            "Kun"
          ],
          "initials": [
            "Z"
          ],
          "authorAffiliationsList": [
            {
              "authorAffiliation": [
                "Department of Pharmacy, The Third Hospital of Jilin University, Jilin University, Changchun, 130033, Jilin, China. Electronic address: zhukun@jlu.edu.cn."
              ]
            }
          ]
        }
      ]
    }
  ],
  "dataLinksTagsList": [
    {
      "dataLinkstag": [
        "supporting_data",
        "altmetrics"
      ]
    }
  ],
  "journalInfo": [
    {
      "journalIssueId": [
        "2933775"
      ],
      "dateOfPublication": [
        "2020 Apr"
      ],
      "monthOfPublication": [
        "4"
      ],
      "yearOfPublication": [
        "2020"
      ],
      "printPublicationDate": [
        "2020-04-01"
      ],
      "journal": [
        {
          "title": [
            "Research in social & administrative pharmacy : RSAP"
          ],
          "ISOAbbreviation": [
            "Res Social Adm Pharm"
          ],
          "medlineAbbreviation": [
            "Res Social Adm Pharm"
          ],
          "NLMid": [
            "101231974"
          ],
          "ISSN": [
            "1934-8150"
          ],
          "ESSN": [
            "1934-8150"
          ]
        }
      ]
    }
  ],
  "pubYear": [
    "2020"
  ],
  "abstractText": [
    "The coronavirus disease-19 (COVID-19) is caused by the novel severe acute respiratory syndrome coronavirus that was first detected at the end of December 2019. The epidemic has affected various regions of China in different degrees. As the situations evolve, the COVID-19 had been confirmed in many countries, and made a assessment that it can be characterized as a pandemic by the World Health Organization on March 11, 2020. Drugs are the main treatment of COVID-19 patients. Pharmaceutical service offers drug safety ensurance for COVID-19 patients. According to COVID-19 prevention and control policy and requirements, combined with series of diagnosis and treatment plans, pharmacists in the first provincial-level COVID-19 diagnosis and treatment unit in Jilin Province in Northeast China have established the management practices of drug supply and pharmaceutical care from four aspects: personnel, drugs supply management, off-label drug use management and pharmaceutical care. During the outbreak, the pharmaceutical department of THJU completed its assigned workload to ensure drug supply. So far, no nosocomial infections and medication errors have occurred, which has stabilized the mood of the staff and boosted the pharmacists' confidence in fighting the epidemic. For the treatment of COVID-19, pharmacists conducted adverse reaction monitoring and participated in the multidisciplinary consultation of COVID-19. Up to now, the COVID-19 patients admitted to THJU have not shown any new serious adverse reactions and been cured finally. The hospital pharmacy department timely adjusted the work mode, and the formed management practices is a powerful guarantee for the prevention and control of the COVID-19 epidemic. This paper summarized the details and practices of drug supply and pharmaceutical services management to provide experience for the people who involving in COVID-19 prevention and contain in other abroad epidemic areas."
  ],
  "affiliation": [
    "Department of Pharmacy, The Third Hospital of Jilin University, Jilin University, Changchun, 130033, Jilin, China."
  ],
  "publicationStatus": [
    "aheadofprint"
  ],
  "language": [
    "eng"
  ],
  "pubModel": [
    "Print-Electronic"
  ],
  "pubTypeList": [
    {
      "pubType": [
        "discussion",
        "Journal Article"
      ]
    }
  ],
  "keywordList": [
    {
      "keyword": [
        "practice",
        "Drug Supply",
        "Pharmaceutical Service",
        "Coronavirus Disease-19 (Covid-19)"
      ]
    }
  ],
  "subsetList": [
    {
      "subset": [
        {
          "code": [
            "IM"
          ],
          "name": [
            "Index Medicus"
          ]
        }
      ]
    }
  ],
  "fullTextUrlList": [
    {
      "fullTextUrl": [
        {
          "availability": [
            "Subscription required"
          ],
          "availabilityCode": [
            "S"
          ],
          "documentStyle": [
            "doi"
          ],
          "site": [
            "DOI"
          ],
          "url": [
            "https://doi.org/10.1016/j.sapharm.2020.04.001"
          ]
        },
        {
          "availability": [
            "Open access"
          ],
          "availabilityCode": [
            "OA"
          ],
          "documentStyle": [
            "html"
          ],
          "site": [
            "Europe_PMC"
          ],
          "url": [
            "https://europepmc.org/articles/PMC7136878"
          ]
        },
        {
          "availability": [
            "Open access"
          ],
          "availabilityCode": [
            "OA"
          ],
          "documentStyle": [
            "pdf"
          ],
          "site": [
            "Europe_PMC"
          ],
          "url": [
            "https://europepmc.org/articles/PMC7136878?pdf=render"
          ]
        },
        {
          "availability": [
            "Open access"
          ],
          "availabilityCode": [
            "OA"
          ],
          "documentStyle": [
            "doi"
          ],
          "site": [
            "DOI"
          ],
          "url": [
            "https://doi.org/10.1016/j.sapharm.2020.04.001"
          ]
        }
      ]
    }
  ],
  "isOpenAccess": [
    "Y"
  ],
  "inEPMC": [
    "Y"
  ],
  "inPMC": [
    "N"
  ],
  "hasPDF": [
    "Y"
  ],
  "hasBook": [
    "N"
  ],
  "hasSuppl": [
    "Y"
  ],
  "citedByCount": [
    "0"
  ],
  "hasData": [
    "Y"
  ],
  "hasReferences": [
    "N"
  ],
  "hasTextMinedTerms": [
    "Y"
  ],
  "hasDbCrossReferences": [
    "N"
  ],
  "hasLabsLinks": [
    "Y"
  ],
  "authMan": [
    "N"
  ],
  "epmcAuthMan": [
    "N"
  ],
  "nihAuthMan": [
    "N"
  ],
  "hasTMAccessionNumbers": [
    "N"
  ],
  "dateOfCreation": [
    "2020-04-23"
  ],
  "firstIndexDate": [
    "2020-04-24"
  ],
  "fullTextReceivedDate": [
    "2020-04-13"
  ],
  "dateOfRevision": [
    "2020-04-24"
  ],
  "electronicPublicationDate": [
    "2020-04-06"
  ],
  "firstPublicationDate": [
    "2020-04-06"
  ]
}